Aug 12, 2026 07:30PM
Aug 12, 2026 07:30PM
Aug 6, 2026 07:00AM
Jul 28, 2026 07:00AM
Jul 28, 2026 07:00AM
May 19, 2026 07:01AM
May 19, 2026 07:00AM Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
May 18, 2026 08:34AM
May 7, 2026 07:00AM
Apr 28, 2026 07:00AM
Apr 28, 2026 07:00AM
Mar 10, 2026 07:00AM
Jan 8, 2026 07:05AM
Jan 8, 2026 07:00AM Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
Dec 8, 2025 10:34AM
Dec 8, 2025 10:31AM
Dec 1, 2025 07:00AM
Dec 1, 2025 07:00AM
Nov 21, 2025 06:40AM
Nov 20, 2025 07:13AM
Nov 20, 2025 07:00AM Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanc
Nov 6, 2025 07:00AM
Oct 12, 2025 06:27PM
Sep 9, 2025 05:30AM
Aug 21, 2025 06:35AM
Aug 7, 2025 07:00AM
Jul 22, 2025 07:01AM
Jul 22, 2025 07:00AM Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
Jun 1, 2025 08:21AM
May 22, 2025 05:15PM
May 8, 2025 07:00AM
Apr 29, 2025 07:03AM
Apr 29, 2025 07:00AM
Apr 23, 2025 10:14AM
Apr 16, 2025 07:00AM Cullinan Therapeutics (CGEM) Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978
Apr 16, 2025 07:00AM
Feb 27, 2025 07:00AM
Jan 30, 2025 06:39AM
Jan 28, 2025 07:00PM
Nov 7, 2024 07:00AM
Oct 17, 2024 06:54AM
Oct 16, 2024 07:00AM Cullinan Therapeutics (CGEM) Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978
Oct 16, 2024 07:00AM
Sep 18, 2024 06:40AM
Sep 18, 2024 06:20AM
Sep 17, 2024 07:00AM
Sep 17, 2024 07:00AM
Sep 16, 2024 07:08AM
Sep 16, 2024 07:02AM Cullinan Therapeutics (CGEM) Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
Sep 16, 2024 07:00AM

328,337 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All